Skip to main content
  • FOR CONSUMERS
  • CONTACT US
Bayer logo Miralax Logo

The information on this page is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL    I AM NOT A HEALTHCARE PROFESSIONAL

Home
  • About MiraLAX®
  • About Constipation
  • Studies & Guidelines
  • Patient Resources & Samples
Bayer Cross Logo
  1. Home
  2. HCP Home - Start with MiraLAX® — the leading brand for relief of occasional constipation

In 2 recent surveys
Patients and HCPs alike reported a negative quality of life (QoL) impact of constipation1,2

In a recent survey of 300 gastroenterologists1,a
approximately 3 out of 4 GIs rated occasional constipation as having a negative impact on their patients’ QoLb


Patient profiles are hypothetical and stories are for illustrative purposes only.

“I can’t tell my boss that I’m late for work again because of constipation. All the walking and getting more water and more high-fiber food—it’s not working.”

Constipation can cause employment issues.2 Start your patients on triple-action MiraLAX® sooner

Meet Carrie

  • Reports straining, hard stools, and defecation <3 times per week
  • Has walked ≥2 miles a day and increased fiber intake for 2 months without improvement
  • First reported occasional constipation years ago
  • 44 years old
  • High school secretary with 2 teenagers at home

In a survey of 557 patients in the Knowledge Networks Panel who reported chronic constipation2
~70% of people had difficulty working, and at least 1 in 10 missed work or school completely due to constipation2

In a recent survey of 300 gastroenterologists1,a

Nearly two-thirds of GIs said

These mechanisms of action are the most important for OTC treatment of OC:

  • Colon hydration
  • Softening and increasing of stool volume
  • Peristalsis that avoids urgency and cramping

and that MiraLAX® provides these more effectively than other OTC treatments

  • Nearly 8 in 10 said effectively treating OC with their first recommendation is a top consideration when choosing an over-the-counter OC treatmentc
  • 90% said MiraLAX® is their most trusted OTC laxative and the one that provides the best balance of efficacy and tolerabilityd

aBased on a survey that asked 300 gastroenterologists to rate the important factors in choosing an OTC medication for adults with OC and how well MiraLAX®met those needs. HCPs selected from a set of options, based on their clinical experience. Survey details and data are available upon request.

b75% of GIs rated the degree of negative impact ≥5 on a scale of 1-7.

c79% of GIs rated the strength of their belief in the importance of this consideration ≥5 on a scale of 1-7.

dGIs rated the strength of their agreement with these statements ≥5 on a scale of 1-7.

 


Start MiraLAX® sooner, because:

  • MiraLAX® binds and retains water in the colon through formation of hydrogen bonds3
  • MiraLAX® molecules incorporate water into the stool, softening and increasing volume4
  • MiraLAX® promotes gentle peristalsis5 without harsh side effects (like those caused by colonic nerve stimulation or metabolization by bacteria)4-7
Image

 

Start your patients like Carrie on MiraLAX® sooner:
Its triple action hydrates, softens, and promotes gentle peristalsis3-5

 


Download Carrie's Profile Meet Annie

Click to expand.

    References

    References: 1. Data on file, Bayer Healthcare. 2. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599–608 3. Schiller LR, Emmett M, Santa Ana CA, Fordtran JS. Osmotic effects of polyethylene glycol. Gastroenterology. 1988;94(4):933-941. doi:10.1016/0016-5085(88)90550-1 4. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest. 1989;84(4):1056-1062. doi:10.1172/JCI114267 5. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):16B-21B. 6. DiPalma JA, DeRidder PH, Orlando RC, et al. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol. 2000;95(2):446-450. doi:10.1111/j.1572-0241.2000.01765.x 7. DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100(11):1085-1090. doi:10.1097/SMJ.0b013e318157ec8f

    MiraLAX HCP
    • Contact Us
      • Site Map
      • About MiraLAX®
      • About Constipation
    • Studies & Guidelines
      • Patient Resources & Samples

    ©2023. All rights reserved. Unless otherwise indicated, all trademarks are owned by Bayer, and its affiliates, or licensed for its use.

    USE AS DIRECTED

    • Bayer Global
    • Bayer US
    • Bayer Consumer Health
    • Conditions of Use
    • Privacy Statement
    • Imprint
    • California Transparency in Supply Chains
    • Satisfaction Guarantee
    • AdChoices
    • Do not sell or share my Personal Data
    • Accessibility

    Level Access website accessibility icon